Atherosclerosis and inflammation: therapeutic targets and ways of correction
Atherosclerosis is a chronic inflammatory vascular disease caused by various risk factors, in particular smoking, obesity, high blood pressure, and dyslipidemia. In addition, such signaling pathways as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-06-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/587 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849772571239645184 |
|---|---|
| author | A. A. Klimenko D. Yu. Andriyashkina K. I. Ogarkova |
| author_facet | A. A. Klimenko D. Yu. Andriyashkina K. I. Ogarkova |
| author_sort | A. A. Klimenko |
| collection | DOAJ |
| description | Atherosclerosis is a chronic inflammatory vascular disease caused by various risk factors, in particular smoking, obesity, high blood pressure, and dyslipidemia. In addition, such signaling pathways as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and Wnt, which are associated with the inflammatory response in the human body, are involved in the pathogenesis of atherosclerosis. Therapeutic targeting of inflammatory pathways, especially the NLRP3 inflammasome pathway and the cascade of reactions regulated by it leading to the production of inflammatory interleukin-1β, may represent a new avenue for the treatment of atherosclerotic diseases. This article summarizes knowledge of the cellular participants and key inflammatory signaling pathways in atherosclerosis, discusses preclinical studies targeting these key pathways in atherosclerosis, clinical trials that will target some of these processes, and the effects of suppressing inflammation and atherosclerosis. |
| format | Article |
| id | doaj-art-12d8f6151e1f42b5b09708ec729a032f |
| institution | DOAJ |
| issn | 1818-8338 |
| language | Russian |
| publishDate | 2024-06-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Klinicist |
| spelling | doaj-art-12d8f6151e1f42b5b09708ec729a032f2025-08-20T03:02:18ZrusABV-pressKlinicist1818-83382024-06-01181123010.17650/1818-8338-2024-18-1-K696423Atherosclerosis and inflammation: therapeutic targets and ways of correctionA. A. Klimenko0D. Yu. Andriyashkina1K. I. Ogarkova2Pirogov Russian National Research Medical University, Ministry of Health of RussiaPirogov Russian National Research Medical University, Ministry of Health of RussiaPirogov Russian National Research Medical University, Ministry of Health of RussiaAtherosclerosis is a chronic inflammatory vascular disease caused by various risk factors, in particular smoking, obesity, high blood pressure, and dyslipidemia. In addition, such signaling pathways as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and Wnt, which are associated with the inflammatory response in the human body, are involved in the pathogenesis of atherosclerosis. Therapeutic targeting of inflammatory pathways, especially the NLRP3 inflammasome pathway and the cascade of reactions regulated by it leading to the production of inflammatory interleukin-1β, may represent a new avenue for the treatment of atherosclerotic diseases. This article summarizes knowledge of the cellular participants and key inflammatory signaling pathways in atherosclerosis, discusses preclinical studies targeting these key pathways in atherosclerosis, clinical trials that will target some of these processes, and the effects of suppressing inflammation and atherosclerosis.https://klinitsist.abvpress.ru/Klin/article/view/587atherosclerosislow-density lipoproteinscholesterolinflammationvascular cellsimmune cellssignaling pathwaysnlrp3 inflammasomeproprotein convertase subtilisin/kexin type 9notch pathwaywnt pathwaylipidlowering drugs |
| spellingShingle | A. A. Klimenko D. Yu. Andriyashkina K. I. Ogarkova Atherosclerosis and inflammation: therapeutic targets and ways of correction Klinicist atherosclerosis low-density lipoproteins cholesterol inflammation vascular cells immune cells signaling pathways nlrp3 inflammasome proprotein convertase subtilisin/kexin type 9 notch pathway wnt pathway lipidlowering drugs |
| title | Atherosclerosis and inflammation: therapeutic targets and ways of correction |
| title_full | Atherosclerosis and inflammation: therapeutic targets and ways of correction |
| title_fullStr | Atherosclerosis and inflammation: therapeutic targets and ways of correction |
| title_full_unstemmed | Atherosclerosis and inflammation: therapeutic targets and ways of correction |
| title_short | Atherosclerosis and inflammation: therapeutic targets and ways of correction |
| title_sort | atherosclerosis and inflammation therapeutic targets and ways of correction |
| topic | atherosclerosis low-density lipoproteins cholesterol inflammation vascular cells immune cells signaling pathways nlrp3 inflammasome proprotein convertase subtilisin/kexin type 9 notch pathway wnt pathway lipidlowering drugs |
| url | https://klinitsist.abvpress.ru/Klin/article/view/587 |
| work_keys_str_mv | AT aaklimenko atherosclerosisandinflammationtherapeutictargetsandwaysofcorrection AT dyuandriyashkina atherosclerosisandinflammationtherapeutictargetsandwaysofcorrection AT kiogarkova atherosclerosisandinflammationtherapeutictargetsandwaysofcorrection |